Precision diagnosis is the keystone of clinical medicine. In East Asians, classical type 1 diabetes is uncommon in patients with youngonset diabetes diagnosed before age of 40, in whom a family history, obesity, and beta-cell and kidney dysfunction are key features. Young-onset diabetes affects one in five Asian adults with diabetes in clinic settings; however, it is often misclassified, resulting in delayed or non-targeted treatment. Complex aetiologies, long disease duration, aggressive clinical course, and a lack of evidence-based guidelines have contributed to variable care standards and premature death in these young patients. The high burden of comorbidities, notably mental illness, highlights the numerous knowledge gaps related to this silent killer. The majority of adult patients with youngonset diabetes are managed as part of a heterogeneous population of patients with various ages of diagnosis. A multidisciplinary care team led by physicians with special interest in young-onset diabetes will help improve the precision of diagnosis and address their physical, mental, and behavioral health. To this end, payors, planners, and providers need to align and re-design the practice environment to gather data systematically during routine practice to elucidate the multicausality of young-onset diabetes, treat to multiple targets, and improve outcomes in these vulnerable individuals.
Medullary thyroid carcinoma (MTC) is a rare neuroendocrine tumor originating from the parafollicular cells. The diagnostic and therapeutic strategies for the condition are different from those used for well-differentiated thyroid cancer. Since the 2015 American Thyroid Association guidelines for the diagnosis and treatment of MTC, the latest, including the National Comprehensive Cancer Network and European Association for Medical Oncology guidelines have been updated to reflect several recent advances in the management of MTC. Advances in molecular diagnosis and postoperative risk stratification systems have led to individualized treatment and follow-up strategies. Multi-kinase inhibitors, such as vandetanib and cabozantinib, can prolong disease progression-free survival with favorable adverse effects. In addition, potent selective rearranged during transfection (RET) inhibitors (selpercatinib and pralsetinib) have shown a promising efficacy in recent clinical trials. This review summarizes the management of MTC in recent guidelines focused on sporadic MTC.
Citations
Citations to this article as recorded by
Molecular imaging and related therapeutic options for medullary thyroid carcinoma: state of the art and future opportunities Alessio Imperiale, Valentina Berti, Mickaël Burgy, Roberto Luigi Cazzato, Arnoldo Piccardo, Giorgio Treglia Reviews in Endocrine and Metabolic Disorders.2024; 25(1): 187. CrossRef
Diffuse C-Cells Hyperplasia Is the Source of False Positive Calcitonin Measurement in FNA Washout Fluids of Thyroid Nodules: A Rational Clinical Approach to Avoiding Unnecessary Surgery Chiara Mura, Rossella Rodia, Silvia Corrias, Antonello Cappai, Maria Letizia Lai, Gian Luigi Canu, Fabio Medas, Pietro Giorgio Calò, Stefano Mariotti, Francesco Boi Cancers.2024; 16(1): 210. CrossRef
Meta-Analysis of the Efficacy and Safety Evaluation of Vandetanib in
the Treatment of Medullary Thyroid Cancer Tong-cheng Xian, Min-ye Yang, Xue-lin Zhang, Jie Wang, Yi Luo Hormone and Metabolic Research.2024;[Epub] CrossRef
Successful localisation of recurrent thyroid cancer using preoperative patent blue dye injection B. O. Evranos, N. Ince, H. Ataş, S. B. Polat, H. Ahsen, N. N. Imga, A. Dirikoc, O. Topaloglu, T. Tutuncu, R. Ersoy, B. Cakir Journal of Endocrinological Investigation.2024;[Epub] CrossRef
Current and future of immunotherapy for thyroid cancer based on bibliometrics and clinical trials Ke Wang, Ying Zhang, Yang Xing, Hong Wang, Minghua He, Rui Guo Discover Oncology.2024;[Epub] CrossRef
Combining radiomics with thyroid imaging reporting and data system to predict lateral cervical lymph node metastases in medullary thyroid cancer Zhiqiang Liu, Xiwei Zhang, Xiaohui Zhao, Qianqian Guo, Zhengjiang Li, Minghui Wei, Lijuan Niu, Changming An BMC Medical Imaging.2024;[Epub] CrossRef
Potentials and future perspectives of multi-target drugs in cancer treatment: the next generation anti-cancer agents Ali Doostmohammadi, Hossein Jooya, Kimia Ghorbanian, Sargol Gohari, Mehdi Dadashpour Cell Communication and Signaling.2024;[Epub] CrossRef
Diagnostic capabilities of PET/CT with 18F-DOPA in biochemical recurrence of medullary thyroid carcinoma: a retrospective study N. V. Tsentr, A. A. Zyryanova, M. A. Rusnak, D. V. Ryzhkova Diagnostic radiology and radiotherapy.2024; 15(1): 87. CrossRef
LINC00887 Acts as an Enhancer RNA to Promote Medullary Thyroid
Carcinoma Progression by Binding with FOXQ1 Daxiang Liu, Wenjing Wang, Yanzhao Wu, Yongle Qiu, Lan Zhang Current Cancer Drug Targets.2024; 24(5): 519. CrossRef
Spontaneous and Treatment-Related Changes of Serum Calcitonin in Medullary Thyroid Cancer: Long-Term Experience in a Patient With Multiple Endocrine Neoplasia Type 2B Zsuzsanna Réti, Ádám Gy. Tabák, Miklós Garami, Ildikó Kalina, Gergely Kiss, Zoltán Sápi, Miklós Tóth, Judit Tőke JCO Precision Oncology.2024;[Epub] CrossRef
False-Negative 68Ga-FAPI PET/CT in Pediatric Thyroid Medullary Carcinoma Seen With 68Ga-DOTATOC PET/CT and 18F-FDG PET/CT Mohamad B. Haidar, Farah A. Abou Zeid, Zarouhie Z. Meguerian, Akram N. Al-Ibraheem, Peter E. Noun Clinical Nuclear Medicine.2024; 49(7): 690. CrossRef
B7-H3 and ICAM-1 are potentially therapeutic targets for thyroid carcinoma Pengtao Song, Yongcan Xu, Guochao Ye Diagnostic Pathology.2024;[Epub] CrossRef
Update on Management of Medullary Thyroid Carcinoma: Focus on Nuclear Medicine Giorgio Treglia, Vittoria Rufini, Arnoldo Piccardo, Alessio Imperiale Seminars in Nuclear Medicine.2023; 53(4): 481. CrossRef
Cabozantinib, Vandetanib, Pralsetinib and Selpercatinib as Treatment for Progressed Medullary Thyroid Cancer with a Main Focus on Hypertension as Adverse Effect Linnea Højer Wang, Markus Wehland, Petra M. Wise, Manfred Infanger, Daniela Grimm, Michael C. Kreissl International Journal of Molecular Sciences.2023; 24(3): 2312. CrossRef
A proposed grading scheme for predicting recurrence in medullary thyroid cancer based on the Ki67 index and metastatic lymph node ratio Pengfei Xu, Di Wu, Xuekui Liu Endocrine.2023; 81(1): 107. CrossRef
Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Adults with Inoperable or Metastatic Somatostatin Receptor-Positive Pheochromocytomas/Paragangliomas, Bronchial and Unknown Origin Neuroendocrine Tumors, and Medullary Thyroid Carcinoma: A Systematic Literatur Marianna Hertelendi, Oulaya Belguenani, Azzeddine Cherfi, Ilya Folitar, Gabor Kollar, Berna Degirmenci Polack Biomedicines.2023; 11(4): 1024. CrossRef
PET/CT with various radiopharmaceuticals in the complex diagnosis of medullary thyroid carcinoma: a review N. V. Tsentr, A. E. Ertman, D. V. Ryzhkova Diagnostic radiology and radiotherapy.2023; 14(2): 31. CrossRef
Physical activity and reduced risk of fracture in thyroid cancer patients after thyroidectomy — a nationwide cohort study Jinyoung Kim, Kyungdo Han, Jin-Hyung Jung, Jeonghoon Ha, Chaiho Jeong, Jun-Young Heu, Se-Won Lee, Jeongmin Lee, Yejee Lim, Mee Kyoung Kim, Hyuk-Sang Kwon, Ki-Ho Song, Ki-Hyun Baek Frontiers in Endocrinology.2023;[Epub] CrossRef
Different RONS Generation in MTC-SK and NSCL Cells Lead to Varying Antitumoral Effects of Alpha-Ketoglutarate + 5-HMF Joachim Greilberger, Katharina Erlbacher, Philipp Stiegler, Reinhold Wintersteiger, Ralf Herwig Current Issues in Molecular Biology.2023; 45(8): 6503. CrossRef
Medullary thyroid carcinoma Maria Rosa Pelizzo, Esmeralda Isabella Mazza, Caterina Mian, Isabella Merante Boschin Expert Review of Anticancer Therapy.2023; 23(9): 943. CrossRef
Mixed medullary‑follicular thyroid carcinoma: A case report and literature review Yonghui Wang, Dandan Yin, Guifang Ren, Zhengjiang Wang, Fanhua Kong Oncology Letters.2023;[Epub] CrossRef
Circulating cell-free DNA (cfDNA) in patients with medullary thyroid carcinoma is characterized by specific fragmentation and methylation changes with diagnostic value Anna Citarella, Zein Mersini Besharat, Sofia Trocchianesi, Tanja Milena Autilio, Antonella Verrienti, Giuseppina Catanzaro, Elena Splendiani, Zaira Spinello, Silvia Cantara, Patrizia Zavattari, Eleonora Loi, Cristina Romei, Raffaele Ciampi, Luciano Pezzul Biomarker Research.2023;[Epub] CrossRef
Advances in Diagnostics and Therapy of Medullary Thyroid Carcinoma (MTC)– A Mini-Review Michał Miciak, Krzysztof Jurkiewicz Clinical Cancer Investigation Journal.2023; 12(5): 1. CrossRef
The Evolving Treatment Landscape of Medullary Thyroid Cancer Marta Laganà, Valentina Cremaschi, Andrea Alberti, Danica M. Vodopivec Kuri, Deborah Cosentini, Alfredo Berruti Current Treatment Options in Oncology.2023; 24(12): 1815. CrossRef
Pralsetinib: chemical and therapeutic development with FDA authorization for the management of RET fusion-positive non-small-cell lung cancers Faraat Ali, Kumari Neha, Garima Chauhan Archives of Pharmacal Research.2022; 45(5): 309. CrossRef
Psychosocial Characteristics and Experiences in Patients with Multiple Endocrine Neoplasia Type 2 (MEN2) and Medullary Thyroid Carcinoma (MTC) Robin Lockridge, Sima Bedoya, Taryn Allen, Brigitte Widemann, Srivandana Akshintala, John Glod, Lori Wiener Children.2022; 9(6): 774. CrossRef
Aggressive clinical course of medullary thyroid microcarcinoma Tamara Janić, Mirjana Stojković, Sanja Klet, Bojan Marković, Beleslin Nedeljković, Jasmina Ćirić, Miloš Žarković Medicinski glasnik Specijalne bolnice za bolesti štitaste žlezde i bolesti metabolizma.2022; 27(85): 63. CrossRef
Comparative evaluation of somatostatin and CXCR4 receptor expression in different types of thyroid carcinoma using well-characterised monoclonal antibodies Max Czajkowski, Daniel Kaemmerer, Jörg Sänger, Guido Sauter, Ralph M. Wirtz, Stefan Schulz, Amelie Lupp BMC Cancer.2022;[Epub] CrossRef
Metastatic Risk Stratification of 2526 Medullary Thyroid Carcinoma Patients: A Study Based on Surveillance, Epidemiology, and End Results Database Minh-Khang Le, Masataka Kawai, Toru Odate, Huy Gia Vuong, Naoki Oishi, Tetsuo Kondo Endocrine Pathology.2022; 33(3): 348. CrossRef
Update on the Diagnosis and Management of Medullary Thyroid Cancer: What Has Changed in Recent Years? Krzysztof Kaliszewski, Maksymilian Ludwig, Bartłomiej Ludwig, Agnieszka Mikuła, Maria Greniuk, Jerzy Rudnicki Cancers.2022; 14(15): 3643. CrossRef
Immunotherapy of Neuroendocrine Neoplasms: Any Role for the Chimeric Antigen Receptor T Cells? Giuseppe Fanciulli, Roberta Modica, Anna La Salvia, Federica Campolo, Tullio Florio, Nevena Mikovic, Alice Plebani, Valentina Di Vito, Annamaria Colao, Antongiulio Faggiano Cancers.2022; 14(16): 3991. CrossRef
Preclinical Evaluation of Novel Tyrosine-Kinase Inhibitors in Medullary Thyroid Cancer Davide Saronni, Germano Gaudenzi, Alessandra Dicitore, Silvia Carra, Maria Celeste Cantone, Maria Orietta Borghi, Andrea Barbieri, Luca Mignani, Leo J. Hofland, Luca Persani, Giovanni Vitale Cancers.2022; 14(18): 4442. CrossRef
Rapid and long-lasting response to selpercatinib of paraneoplastic Cushing’s syndrome in medullary thyroid carcinoma Marine Sitbon, Porhuoy Chou, Seydou Bengaly, Brigitte Poirot, Marie Laloi-Michelin, Laure Deville, Atanas Pachev, Ahouefa Kowo-Bille, Clement Dumont, Cécile N Chougnet European Thyroid Journal.2022;[Epub] CrossRef
Ginsenoside Rg3 Alleviates Antithyroid Cancer Drug Vandetanib-Induced QT Interval Prolongation Juan Zhang, Dan Luo, Fang Li, Zhiyi Li, Xiaoli Gao, Jie Qiao, Lin Wu, Miaoling Li, Shao Liang Oxidative Medicine and Cellular Longevity.2021; 2021: 1. CrossRef
THE ROLE OF CALCITONIN IN THE PREOPERATIVE STAGE AS THE PREDICTOR OF MEDULLARY THYROID CANCER METASTASES Volodymyr Palamarchuk , Viktor Smolyar , Oleksandr Tovkay, Oleksandr Nechay, Volodymyr Kuts , Revaz Sichinava , Oleh Mazur Ukrainian Scientific Medical Youth Journal.2021; 127(4): 68. CrossRef
THE ROLE OF CALCITONIN IN THE PREOPERATIVE STAGE AS THE PREDICTOR OF MEDULLARY THYROID CANCER METASTASES Volodymyr Palamarchuk , Viktor Smolyar , Oleksandr Tovkay , Oleksandr Nechay , Volodymyr Kuts , Revaz Sichinava , Oleh Mazur The Ukrainian Scientific Medical Youth Journal.2021; 4(127): 68. CrossRef
Background Pheochromocytoma and paragangliomas (PPGL) are hereditary in approximately 30% to 40% cases. With the advancement of genetic analysis techniques, including next-generation sequencing (NGS), there were attempts to classify PPGL into molecular clusters. With NGS being applied to clinical settings recently, we aimed to review the results of genetic analysis, including NGS, and investigate the association with clinical characteristics in Korean PPGL patients.
Methods We reviewed the medical records of PPGL patients who visited Severance hospital from 2006 to 2019. We documented the clinical phenotype of those who underwent targeted NGS or had known germline mutations of related genes.
Results Among 57 PPGL patients, we found 28 pathogenic germline mutations of susceptibility genes. Before the targeted NGS was implemented, only obvious syndromic feature lead to the Sanger sequencing for the specific genes. Therefore, for the exact prevalence, only patients after the year 2017, when targeted NGS was added, were included (n=43). The positive germline mutations were found in 14 patients; thus, the incidence rate is 32.6%. Patients with germline mutations had a higher likelihood of family history. There were significant differences in the type of PPGLs, percentage of family history, metastasis rate, presence of other tumors, and biochemical profile among three molecular clusters: pseudohypoxic tricarboxylic acid cycle-related, pseudohypoxic von Hippel-Lindau (VHL)/endothelial PAS domain-containing protein 1-related, and kinase-signaling group. Germline mutations were identified in seven PPGL-related genes (SDHB, RET, VHL, NF1, MAX, SDHA, and SDHD).
Conclusion We report the expected prevalence of germline mutations in Korean PPGL patients. NGS is a useful and accessible tool for genetic analysis in patients with PPGLs, and further research on molecular classification is needed for precise management.
Citations
Citations to this article as recorded by
Patient Sex and Origin Influence Distribution of Driver Genes and Clinical Presentation of Paraganglioma Susan Richter, Nicole Bechmann Journal of the Endocrine Society.2024;[Epub] CrossRef
Main mechanisms and clinical implications of alterations in energy expenditure state among patients with pheochromocytoma and paraganglioma: A review Yuqi Yang, Tong Zhou, Xue Zhao, Yunjia Cai, Yao Xu, Xiaokun Gang, Guixia Wang Medicine.2024; 103(17): e37916. CrossRef
Validation and Evaluation of 5 Scoring Systems for Predicting Metastatic Risk in Pheochromocytoma and Paraganglioma Qin Li, Zhigang Lan, Yong Jiang, Rui Wang, Ziyao Li, Xiaolin Jiang American Journal of Surgical Pathology.2024;[Epub] CrossRef
Novel and recurrent genetic variants of VHL, SDHB, and RET genes in Chinese pheochromocytoma and paraganglioma patients Chong Li, Jingyi Li, Chao Han, Ting Wang, Lixia Zhang, Zhifang Wang, Tingting Wang, Lijun Xu, Guangzhao Qi, Guijun Qin, Xialian Li, Lili Zheng Frontiers in Genetics.2023;[Epub] CrossRef
Genetic Study in Pheochromocytoma: Is It Possible to Stratify the Risk of Hereditary Pheochromocytoma? Marta Araujo-Castro, César Mínguez Ojeda, Iñigo García Sanz, Maria Calatayud, Felicia Hanzu, Mireia Mora, Almudena Vicente, Concepción Blanco Carrera, Paz de Miguel Novoa, María del Carmen López García, Cristina Lamas, Laura Manjón-Miguélez, María del Cas Neuroendocrinology.2023; 113(6): 657. CrossRef
The Role of VHL in the Development of von Hippel-Lindau Disease and Erythrocytosis Petra Hudler, Mojca Urbancic Genes.2022; 13(2): 362. CrossRef
Bilateral Pheochromocytoma with Germline MAX Variant without Family History Shinnosuke Hata, Mai Asano, Hiroyuki Tominaga, Masahide Hamaguchi, Fumiya Hongo, Takeshi Usui, Eiichi Konishi, Michiaki Fukui Clinics and Practice.2022; 12(3): 299. CrossRef
Diagnosis for Pheochromocytoma and Paraganglioma: A Joint Position Statement of the Korean Pheochromocytoma and Paraganglioma Task Force Eu Jeong Ku, Kyoung Jin Kim, Jung Hee Kim, Mi Kyung Kim, Chang Ho Ahn, Kyung Ae Lee, Seung Hun Lee, You-Bin Lee, Kyeong Hye Park, Yun Mi Choi, Namki Hong, A Ram Hong, Sang-Wook Kang, Byung Kwan Park, Moon-Woo Seong, Myungshin Kim, Kyeong Cheon Jung, Chan Endocrinology and Metabolism.2021; 36(2): 322. CrossRef
Prevalence of Germline Variants in a Large Cohort of Japanese Patients with Pheochromocytoma and/or Paraganglioma Masato Yonamine, Koichiro Wasano, Yuichi Aita, Takehito Sugasawa, Katsutoshi Takahashi, Yasushi Kawakami, Hitoshi Shimano, Hiroyuki Nishiyama, Hisato Hara, Mitsuhide Naruse, Takahiro Okamoto, Tadashi Matsuda, Shinji Kosugi, Kazuhiko Horiguchi, Akiyo Tanab Cancers.2021; 13(16): 4014. CrossRef
Recurrent Germline Mutations of CHEK2 as a New Susceptibility Gene in Patients with Pheochromocytomas and Paragangliomas Yinjie Gao, Chao Ling, Xiaosen Ma, Huiping Wang, Yunying Cui, Min Nie, Anli Tong, Dario De Biase International Journal of Endocrinology.2021; 2021: 1. CrossRef
Acromegaly presents with an enigmatic range of symptoms and comorbidities caused by chronic and progressive growth hormone elevations, commonly due to endocrinologic hypersecretion from a pituitary gland tumor. Comprehensive national acromegaly databases have been appearing over the years, allowing for international comparisons of data, although still presenting varying prevalence and incidence rates. Lack of large-scale analysis in geographical and ethnic differences in clinical presentation and management requires further research. Assessment of current and novel predictors of responsiveness to distinct therapy can lead to multilevel categorization of patients, allowing integration into new clinical guidelines and reduction of increased morbidity and mortality associated with acromegaly. This review compares current data from epidemiological studies and assesses the present-day application of prognostic factors in medical practice, the reality of precision therapy, as well as its future prospects in acromegaly, with a special focus on its relevance to the South Korean population.
Citations
Citations to this article as recorded by
Biomarkers of response to treatment in acromegaly Leandro Kasuki, Elisa Lamback, Ximene Antunes, Mônica R. Gadelha Expert Review of Endocrinology & Metabolism.2024; 19(1): 71. CrossRef
Predictors of morphofunctional features of somatotrophic tumors and of the effectiveness of treatment with first-generation somatostatin receptor ligands E. V. Pronin, V. S. Pronin, M. B. Antsiferov, A. V. Petryaykin, T. M. Alexeeva, A. M. Lapshina, L. S. Urusova, A. N. Khoruzhaya, S. M. Tamaeva Meditsinskiy sovet = Medical Council.2024; (6): 98. CrossRef
Multiomics Approach to Acromegaly: Unveiling Translational Insights for Precision Medicine Kyungwon Kim, Cheol Ryong Ku, Eun Jig Lee Endocrinology and Metabolism.2023; 38(5): 463. CrossRef
Risk of depression in patients with acromegaly in Korea (2006-2016): a nationwide population-based study Shinje Moon, Sangmo Hong, Kyungdo Han, Cheol-Young Park European Journal of Endocrinology.2023; 189(3): 363. CrossRef
The Future of Somatostatin Receptor Ligands in Acromegaly Monica R Gadelha, Luiz Eduardo Wildemberg, Leandro Kasuki The Journal of Clinical Endocrinology & Metabolism.2022; 107(2): 297. CrossRef
Innovative therapeutics in acromegaly Leandro Kasuki, Mônica R. Gadelha Best Practice & Research Clinical Endocrinology & Metabolism.2022; 36(6): 101679. CrossRef
Risk of Neurodegenerative Diseases in Patients With Acromegaly Sangmo Hong, Kyungdo Han, Kyung-Soo Kim, Cheol-Young Park Neurology.2022;[Epub] CrossRef
Machine Learning-based Prediction Model for Treatment of Acromegaly With First-generation Somatostatin Receptor Ligands Luiz Eduardo Wildemberg, Aline Helen da Silva Camacho, Renan Lyra Miranda, Paula C L Elias, Nina R de Castro Musolino, Debora Nazato, Raquel Jallad, Martha K P Huayllas, Jose Italo S Mota, Tobias Almeida, Evandro Portes, Antonio Ribeiro-Oliveira, Lucio Vi The Journal of Clinical Endocrinology & Metabolism.2021; 106(7): 2047. CrossRef
Skin anomalies in acromegalic patients (Review of the practical aspects) Florica Sandru, Adelina Popa, Dan Paduraru, Alexandru Filipescu, Mara Carsote, Adina Ghemigian Experimental and Therapeutic Medicine.2021;[Epub] CrossRef